[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543487":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":44,"locations":54,"responsibleParty":67,"collaborators":10,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":10,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":10,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":91,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Modeling group",null,"The data of modeling group is used to construct a predictive model of AIH end-point events.",{"label":13,"type":10,"description":14,"interventionNames":10},"Validation group","Validation group is used to validate the predictive model externally.",[16,19,22,26,29,32,35,38,41],{"name":17,"affiliation":5,"role":18},"Xinyan Zhao","STUDY_CHAIR",{"name":20,"affiliation":21,"role":18},"Zhengsheng Zou","Beijing 302 Hospital",{"name":23,"affiliation":24,"role":25},"Yu Chen","Beijing You 'an Hospital, Capital Medical University","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":25},"Jia Li","Tianjin Second People's Hospital",{"name":30,"affiliation":31,"role":25},"Jingshou Chen","The First Affiliated Hospital of Xiamen University",{"name":33,"affiliation":34,"role":25},"Liang Wang","Lanzhou University Second Hospital",{"name":36,"affiliation":37,"role":25},"Huahua Wang","Jiaozuo People's Hospital",{"name":39,"affiliation":40,"role":25},"Xiaoli Hu","Heilongjiang Provincinal Hospital",{"name":42,"affiliation":43,"role":25},"Pingying Li","Qinghai People's Hospital",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":10,"email":49},"Yu Su","CONTACT","18810639513","suyu_7912@163.com",{"name":51,"role":47,"phone":52,"phoneExt":10,"email":53},"Qianyi Wang","18519667363","wangqy1001@hotmail.com",[55],{"facility":56,"status":10,"city":57,"state":10,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":10},"Beijing Friendship Hospital, Capital Medical University","Beijing","100050","China","CN",{"type":62,"coordinates":63},"Point",[64,65],116.39723,39.9075,{"lat":65,"lon":64},{"type":25,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Zhao Xinyan","Director, Principal Investigator, Clinical Professor","100543487","a-study-on-factors-of-biochemical-response-in-autoimmune-hepatitis-100543487",false,"NCT06356506","A Study on Factors of Biochemical Response in Autoimmune Hepatitis","A Multicenter, Prospective Cohort Study on the Influencing Factors of Biochemical Response in Autoimmune Hepatitis","Inclusion Criteria:\n\n1. ≥18 years old at the time of onset;\n2. AIH simplified score ≥6 and\u002For AIH revised score ≥10;\n3. Liver biopsy was performed and consistent with the pathological diagnosis of AIH;\n4. Patents were treatment naive or who were diagnosed and treated in other hospitals but have stopped glucocorticoid\u002Fimmunosuppressive therapy for more than 3 months;\n5. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. concomitant liver diseases: hepatotropic viral hepatitis (A, B, C, D, and E) and non-hepatotropic viral hepatitis (cytomegalovirus and Epstein-Barr virus (EBV) infection);\n2. concomitant with drug-induced liver injury, primary biliary cholangitis, primary sclerosing cholangitis, alcoholic liver disease, genetic and metabolic liver diseases;\n3. bone marrow or liver transplantation;\n4. incomplete baseline medical history and laboratory examination results;\n5. for previously diagnosed patients, immunosuppressive therapy was discontinued less than 3 months;\n6. Pregnancy or lactation;\n7. patients with contraindications to glucocorticoid\u002Fimmunosuppressive therapy;\n8. complicated with other malignant tumors;\n9. complicated with mental disorders.","ALL","18 Years",{"count":80,"type":81},630,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to clarify the clinical characteristics of autoimmune hepatitis (AIH) in China. The main questions it aims to answer are:\n\nHuman leukocyte antigen (HLA) gene susceptibility in Chinese AIH patients prognostic factors associated with AIH Participants will provide liver tests results and details of treatment during follow-up.",[85],"Autoimmune Hepatitis",[87,88,89,90],"Autoimmune hepatitis","Biochemical response","Prognosis","Immunosuppressive therapy","NOT_YET_RECRUITING","2024-04-18",{"date":94,"type":95},"2024-04-19","ACTUAL",{"date":97,"type":81},"2024-05-01",{"date":99,"type":81},"2034-05-01",{"name":5,"class":6},1]